Howard Lopes Ribeiro

GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?

Abstract Objective Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual/triple agonists, have revolutionized the management of obesity and type 2 diabetes. However, hair loss has emerged as an adverse event in clinical practice. This...